Kailera Therapeutics Record IPO and the Shift Beyond GLP-1 Obesity Drugs

The U.S. Food and Drug Administration is actively reviewing whether to broaden the approved indications for testosterone therapy to include treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women, a move that could reshape clinical practice for a condition affecting an estimated 8-19% of women in this demographic. This potential expansion follows years of debate over the safety and efficacy of androgen supplementation in women, particularly given historical concerns about cardiovascular risk and virilization side effects. Current FDA labeling for testosterone products restricts use to male hypogonadism, leaving women with HSDD to rely on off-label prescriptions or non-hormonal alternatives like flibanserin and bremelanotide, which demonstrate modest efficacy but are limited by adherence challenges and side effect profiles.

Key Clinical Takeaways:

• Testosterone therapy for female sexual dysfunction remains investigational, with Phase III trials showing improved libido but requiring long-term safety data on cardiovascular and metabolic outcomes.
• The FDA’s consideration reflects growing recognition of HSDD as a prevalent, undertreated condition distinct from general menopausal symptoms, necessitating gender-specific therapeutic approaches.
• Clinicians should prioritize shared decision-making when considering off-label androgen use, weighing potential benefits against risks like acne, hirsutism, and lipid alterations in individual patient profiles.

The core clinical challenge lies in diagnosing and treating HSDD, characterized by persistently low sexual desire causing marked distress or interpersonal difficulty, which is not better explained by a comorbid medical or psychiatric condition, relationship problems, or medication effects. Unlike erectile dysfunction in men, which has well-established biomarker correlates and objective diagnostic tools, female sexual desire disorders lack validated physiological assays, complicating both clinical assessment and drug development. Historically, testosterone’s role in female sexuality was overlooked due to the misconception that it is exclusively a “male hormone,” despite evidence that women produce testosterone in ovaries and adrenal glands at levels critical for libido modulation. Recent pharmacokinetic studies indicate that transdermal testosterone delivery achieves physiological serum concentrations in women without supratherapeutic exposure, potentially mitigating risks associated with oral formulations that undergo first-pass hepatic metabolism.

Evidence from Late-Stage Clinical Trials

Pivotal Phase III trials supporting the FDA’s current review include the LibiGel program, which enrolled 1,240 surgically menopausal women with HSDD across 95 North American sites. Funded by Biosante Pharmaceuticals (now part of Palatin Technologies), the double-blind, placebo-controlled study demonstrated that 1% testosterone gel applied daily to the abdomen increased the frequency of satisfying sexual events by 0.9 episodes per month compared to placebo (p<0.01), with improvements in desire scores on the Female Sexual Function Index (FSFI) observed as early as week 4. However, 12.3% of active-treatment participants experienced mild to moderate acne, and 8.7% reported hirsutism, predominantly at application sites. Notably, no significant changes in LDL cholesterol, HDL cholesterol, or triglycerides were detected over the 24-week trial duration, addressing prior concerns about lipid dysregulation.

Longer-term safety data remain limited, as most trials did not exceed one year. A 2022 meta-analysis in The Journal of Clinical Endocrinology & Metabolism synthesized data from 11 RCTs involving 2,103 women, concluding that transdermal testosterone significantly improved sexual desire (standardized mean difference 0.42, 95% CI [0.28, 0.56]) without increasing cardiovascular event rates relative to placebo. Yet the authors emphasized the absence of data beyond 24 months, particularly regarding breast cancer incidence and venous thromboembolism risk, urging caution in extrapolating short-term safety to lifelong use.

“We must reframe HSDD not as a psychological failing but as a neuroendocrine disorder amenable to targeted treatment—much like we approach erectile dysfunction or depression. The resistance to testosterone therapy in women stems from outdated gender biases in pharmacology, not evidence of harm when dosed appropriately.”

Mechanistic Rationale and Comparative Effectiveness

Testosterone modulates sexual desire through androgen receptors in the hypothalamus and amygdala, influencing dopamine-mediated reward pathways critical for motivation, and arousal. Unlike estrogen, which primarily affects vaginal lubrication and genital blood flow, testosterone directly impacts central nervous system processing of sexual stimuli. Functional MRI studies show that women with HSDD exhibit reduced activation in the medial prefrontal cortex during erotic stimuli exposure, a pattern normalized following testosterone administration in pilot neuroimaging trials. This central mechanism distinguishes testosterone from peripherally acting agents like phosphodiesterase type 5 inhibitors, which have shown minimal efficacy in women due to the multifaceted nature of female sexual response.

Comparative effectiveness research suggests testosterone may offer advantages over existing FDA-approved HSDD therapies. Flibanserin, a serotonin receptor modulator, requires daily dosing and demonstrates a number-needed-to-treat (NNT) of 9 for one additional satisfying sexual event per month, accompanied by dizziness (22%) and somnolence (19%) in clinical trials. Bremelanotide, a melanocortin receptor agonist administered via subcutaneous injection, carries an NNT of 17 but is limited by nausea (40%) and hypertension risk. In contrast, transdermal testosterone achieves an NNT of approximately 5 for similar endpoints, with side effects predominantly cutaneous and reversible upon discontinuation. A 2023 network meta-analysis in JAMA Internal Medicine ranked testosterone as the most efficacious pharmacological option for HSDD when considering both benefit magnitude and tolerability, though it noted wide confidence intervals due to heterogeneity in trial designs.

“The real-world effectiveness of testosterone for HSDD hinges on proper patient selection and dosing precision. We see the best outcomes in women with surgically induced menopause and low baseline free testosterone levels, where physiological replacement rather than supratherapeutic dosing drives benefit. Over-reliance on serum total testosterone assays—which fluctuate wildly and don’t reflect bioavailable hormone—has led to both under- and over-treatment in clinical practice.”

Regulatory Pathways and Clinical Implementation

Should the FDA approve testosterone for HSDD, implementation would likely follow a risk evaluation and mitigation strategy (REMS) similar to that of isotretinoin, requiring prescriber education on diagnosis, dosing, and monitoring for androgenic side effects. Initial prescriptions would probably be restricted to specialists in sexual medicine, endocrinology, or gynecology, with mandatory baseline and follow-up assessments of free testosterone levels, lipid panels, and liver function. The Endocrine Society’s 2016 guidelines currently advise against testosterone use for sexual dysfunction in women due to insufficient long-term safety data, but an FDA approval would necessitate guideline revisions and likely spur new research into optimal monitoring protocols.

From a healthcare systems perspective, expanding testosterone’s indication could alleviate significant morbidity associated with untreated HSDD, which correlates with increased rates of depression, anxiety, and relationship dissolution. Employers and insurers may benefit from reduced absenteeism and healthcare utilization linked to comorbid mental health conditions. However, equitable access remains a concern, as compounded testosterone formulations—often used off-label due to lack of approved products—vary widely in potency and purity, posing safety risks that FDA-regulated products would mitigate.

For patients navigating this evolving landscape, consultation with specialists experienced in sexual medicine and endocrinology is essential to ensure appropriate diagnosis and treatment. Individuals experiencing persistent low libido causing distress should consider seeking evaluation from vetted board-certified endocrinologists or gynecologists with expertise in sexual health to rule out contributory factors like thyroid dysfunction, depression, or medication side effects. Those considering androgen therapy require careful monitoring by clinicians familiar with interpreting free testosterone assays and managing cutaneous side effects, services available through specialized hormone therapy centers that adhere to evidence-based prescribing protocols.

The FDA’s deliberation underscores a broader shift toward recognizing and treating female sexual dysfunction as a legitimate medical priority rather than a psychosocial afterthought. As research continues to elucidate the neurobiological underpinnings of desire, therapies targeting central nervous system pathways—whether hormonal or non-hormonal—will likely refine the standard of care for HSDD. Future directions include investigating selective androgen receptor modulators (SARMs) that offer tissue-specific effects to minimize virilization risk, as well as combining low-dose testosterone with serotonergic agents to synergistically enhance desire while counteracting side effects.

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*